Radioiodine (I-131) uptakes and hormonal (T4) levels in hyperthyroid patients receiving radioiodine therapy while on anti-thyroid drugs and relation to incidence of hypothyroidism at one year.
Radioactive iodine (I-131) uptakes (RAIU) and serum T4 levels were observed in 72 patients referred for radioiodine therapy. Of 65 patients whose results could be evaluated 47 had these tests while on carbiomazole (CMZ). 17 of these 47 patients had repeat tests a week later and the differences were not significant. In the remaining 18 patients of the 65, the tests were performed after stopping the CMZ for 1-5 days and again at 8-12 days. The differences in the results were again not significant. The incidence of hypothyroidism at 1 year was noted in the group receiving radioiodine therapy while on CMZ as compared to those stopping the CMZ for 1-12 days. The difference was again not significant, though the number of these patients becoming hypothyroid was small. Serum T4 levels were measured in 21 patients, two weeks after treatment with radioiodine and there was no real difference from the baseline T4 levels.
D000328:Adult; D000368:Aged; D002231:Carbimazole / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006111:Graves Disease / Q000000981:diagnostic imaging; D006801:Humans; D006980:Hyperthyroidism / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D007037:Hypothyroidism / Q000000981:diagnostic imaging*; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D013974:Thyroxine / Q000097:blood*
D007457:Iodine Radioisotopes; D002231:Carbimazole; D013974:Thyroxine